Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Says Genzyme Integration Is On Track, But Fabrazyme Production Won't Meet Goals

This article was originally published in The Pink Sheet Daily

Executive Summary

Full production of the rare disease drug is pushed back a quarter, but analysts warm to Sanofi's full-year guidance and ability to meet overall goals for R&D and Genzyme integration.

You may also be interested in...

Genzyme’s Framingham Plant Clears FDA; Restoring Full Supply Could Take All Year

The subsidiary of Sanofi long has pegged opening of additional plant as critical to restoring full production of Fabrazyme, which has been rationed to Fabry disease patients since a manufacturing interruption in 2009.

Aiming For Better, Cheaper ERT Drugs, Oxyrane Raises $26.5 Mil.

U.K biotech Oxyrane raises $26.5 million D round to advance enzyme replacement therapies and validate a technology platform that may lead to cheaper-to-produce and more effective ERTs

As Pharma Falters, Shire Specialist Model Hits Sweet Spot

With product sales growth that most big pharmas can only dream of, Shire's specialist model is working.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts